Please assess the completion status of the following clinical trial:

Trial Title: Flaxseed in Preventing Breast Cancer in Premenopausal Women at Risk of Developing Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* Patients enrolled in must meet ≥ 1 of the following criteria:~  * History of unilateral or bilateral atypical ductal hyperplasia with or without family history~ * History of atypical lobular hyperplasia or lobular carcinoma in situ with or without family history~ * History of ductal carcinoma in situ~ * Prior stage I breast cancer allowed provided it was adequately treated and therapy was completed ≥ 1 year ago~ * Lifetime risk for developing breast cancer \> 20% (based on Gail or Claus model)~ * No abnormal mammogram requiring short-term follow-up within the past 6 months~ * No severe atypia or carcinoma cells on RPRNA~PATIENT CHARACTERISTICS:~* Premenopausal~* ECOG performance status 0-1~* Patients enrolled must meet the following criteria:~  * No peri- or postmenopausal status as determined by estradiol levels \< 20 ng/dL and FSH levels \> 45 ng/dL~ * No thrombocytopenia (defined as platelet count \< 50,000/mm\^3)~ * Creatinine ≤ 1.5 mg/dL~ * Not pregnant or nursing~ * Fertile patients must use effective contraception consistently~ * No other prior malignancy allowed except for the following:~    * Basal cell or squamous cell carcinoma~   * In situ cervical cancer~ * No history of any of the following conditions within the past 5 years:~    * Crohn disease~   * Ulcerative colitis~   * Inflammatory bowel disease~   * Irritable bowel syndrome~   * Celiac sprue~   * Malabsorption syndrome~   * Diverticulitis~   * Diverticulosis~ * No allergy to flaxseed, other seeds or nuts, or wheat~PRIOR CONCURRENT THERAPY:~* Patients enrolled in part 1 must meet the following criteria:~  * No prior breast implants or tram-flap reconstruction~    * Breast reduction allowed~ * No prior neoadjuvant chemotherapy or other chemotherapy within the past year~ * No prior neoadjuvant hormonal therapy~ * No prior whole radiation to the contralateral breast undergoing random periareolar fine needle aspiration (RPFNA)~ * No concurrent coumadin or other chronic anticoagulants (even if they are held for surgery)~* Patients enrolled in part 2 must meet the following criteria:~  * More than 1 year since prior chemotherapy and adjuvant hormonal therapy for breast cancer~    * No concurrent chemotherapy for breast cancer~ * At least 1 month since prior and no concurrent treatment with corticosteroid~ * At least 2 weeks since prior and no concurrent use of antibiotics~ * At least 2 weeks~ * No history of chest wall irradiation~ * No presence of breast implants~ * No prior or concurrent tamoxifen within the past 90 days~ * No chronic/concurrent medications that inhibit platelet function, including any of the following:~    * Aspirin~   * Non-steroidal anti-inflammatory drugs (i.e., Aleve®, Motrin®, ibuprofen)~   * Coumadin~   * Heparin~   * Low molecular weight heparin~   * Anti-platelet agents~      * No prior short-term use of platelet inhibitors ≥ 7 days prior to RPFNA~ * No concurrent ingestion of the following:~    * Pumpkin seeds~   * Sesame seeds~   * Fish oil supplements~ * At least 30 days since prior and no concurrent flaxseed supplements, fish oil, or flaxseed oil~ * No concurrent treatment for another malignancy

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Intervention (Type: EXPERIMENTAL): Patients ingest ground flaxseed daily, with already prepared foods, for 6 months.
- Arm 2: Observational (Type: OTHER): Patients do not receive ground flaxseed.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues